Osteoporosis is more common in patients with inflammatory bowel disease (IBD) compared with the normal population, and causes significant morbidity when fractures occur." One study identified that 25% of women had a bone mineral density more than 2 standard deviations below normals.2 Increased rates of spinal bone loss have been reported in some patients and the average spinal bone loss was 3%/yr. 5 Hormone replacement therapy (HRT) is effective in the prevention and treatment of postmenopausal bone loss."' HRT also reduces the risk of fracture, but there have been no studies of its effect in patients with inflammatory bowel disease.1 '22 We have studied postmenopausal women with inflammatory bowel disease given HRT for two years and followed up changes in their bone density by annual measurements. Patients were given a 'standard dose' of oral oestrogen, which has been shown to prevent bone loss in normal women. 23 32) . Eight patients were current smokers.
All patients were advised to achieve a daily intake of at least 700 mg of calcium; five patients were unable to take sufficient dairy products to sustain this and were given oral calcium supplements. Vitamin D was not prescribed. None were receiving thyroxine, anti-convulsants, thiazide diuretics, sodium fluoride, calcitonin, or bisphosphonates.
The risks and benefits of HRT were first explained with the aims of the study. All patients were given 0-625 mg daily of oral conjugated oestrogen (Premarin, Wyeth). Thirty seven who had not had a hysterectomy were given cyclic progestogen with 150 micrograms of norgestrel for 12 days each month in addition to 0-625 mg of conjugated oestrogen (Prempak C 0.625, Wyeth). This dose of oestrogen has previously been shown to be the minimum required to prevent bone loss in normal menopausal women.23 24 Over the subsequent two years, details of corticosteroid use and surgery were recorded although biochemical parameters were not monitored. There were no adverse effects from the oestrogen therapy apart from breast tenderness in some patients that resolved without treatment. Those receiving cyclic progestogen had regular withdrawal bleeds. Bone density was measured initially and then annually for two years. The same instruments and techniques were used for all the measurements.
DATA ANALYSIS
Each value of bone mineral content/bone width was converted to a Z-score relative to age and sex dependent norms ((patient value -mean)/standard deviation) using the reference data of Ringe.32 Each value for bone mineral density was converted to a Z-score (Z-bone mineral density) using the reference data of Cann and Genant.3'
Each patient had three measurements of bone mineral density and rates of bone loss were estimated by linear regression for each subject. The annual percentage changes in bone mineral content/bone width and bone mineral density were calculated by (slope/intercept) x 100. Statistical analysis was performed using correlation coefficients, t tests, and Mann-Whitney U test.
Statistical significance was taken as p<0 05.
Results Table I summarises the results.
The mean percentage change for bone mineral content/bone width (95% confidence intervals) was +1I42%/yr (+0 58 to +2 26) and for bone mineral density was +2-60%/yr (+1 06 to +4-15) (Table I ). Figure 1 shows the cumulative absolute changes in radial BMC/BW and spinal BMD after ranking each patient by age.
The increase in both forearm and spinal bone mineral density achieved statistical significance in absolute units, percentage per annum, and also in the Z-score. Figures 2 and 3 show the percentage changes in bone mineral density.
There was no significant correlation between the baseline values of BMC/BW or BMD and the subsequent changes in bone mineral or between the rates of change of spinal and radial bone mineral density. There was no significant correlation between the improvements in bone mineral density and the patient's age or the number of years postmenopause.
Twelve patients (seven Crohn's disease) received a mean daily dose of 3-9 mg of prednisolone (range 0 5 to 10 mg) during the two years. The rate of change of spinal trabecular bone (bone mineral density) was lower in those given corticosteroids, but this was not statistically significant (Table II, Fig 2) . The correlations between steroid dose and the changes in bone mineral density were not statistically significant.
Three patients had surgery during the second year of the study; two with total ulcerative colitis had a colectomy, and one patient had a terminal ileal resection. All were given prednisolone before surgery.
There was no significant difference in the response to HRT between patients with ulcerative colitis and Crohn's disease, smokers and non-smokers, and those who had had a hysterectomy and those who had not. There was no significant change in the patient's height, weight, or body mass index during the study. 41 For clinicians without access to bone densitometry, these results are helpful in showing that the improvement with HRT was similar in both Crohn's disease and ulcerative colitis; in addition, the response to oestrogens was not related to the patients age or the number of postmenopausal years.
In view of the increased prevalence of osteoporosis and high rates of bone loss in some 
